Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21831184 | 1.00 | SIGMAR1 (0.39) | SIGMAR1DPP8CYP2D6CYP19A1SLC6A2 | |
| SCHEMBL21831186 | 1.00 | SIGMAR1 (0.39) | SIGMAR1DPP8CYP2D6CYP19A1SLC6A2 | |
| Hydrochloric Acid SCHEMBL30910922 | 0.98 | SIGMAR1 (0.38) | SIGMAR1DPP8CYP2D6CYP19A1SLC6A2 | |
| SCHEMBL21831479 | 0.84 | CYP2D6 (0.56) | SIGMAR1CYP2D6CYP19A1SLC6A2SLC6A4 | |
| SCHEMBL15093683 | 0.84 | CYP2D6 (0.56) | SIGMAR1CYP2D6CYP19A1SLC6A2SLC6A4 | |
| SCHEMBL4153276 | 0.83 | MEN1 (0.53) | CYP2D6SLC6A3KCNH2OPRM1OPRD1 | |
| SCHEMBL4153281 | 0.83 | MEN1 (0.53) | CYP2D6SLC6A3KCNH2OPRM1OPRD1 | |
| SCHEMBL21831225 | 0.83 | OPRM1 (0.40) | SIGMAR1CYP2D6CYP19A1SLC6A2SLC6A4 | |
| SCHEMBL21831226 | 0.83 | OPRM1 (0.40) | SIGMAR1CYP2D6CYP19A1SLC6A2SLC6A4 | |
| SCHEMBL21910237 | 0.83 | OPRM1 (0.40) | SIGMAR1CYP2D6CYP19A1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583876-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | Juno Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-120152717-A | Combination of T cell therapy and continuous or intermittent DGK inhibitor administration | 朱诺治疗学股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117693508-A | Combination of T cell therapy and DGK inhibitors | 朱诺治疗学股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4301755-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | Juno Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230089255-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-03-23 | — | — | US | disclosed |
| CN-115243721-A | Combination of DGK inhibitors and checkpoint antagonists | 百时美施贵宝公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| WO-2022187406-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | SIGMAR1 3220/4885DPP8 3019/4885CYP2D6 3712/4885 |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | SIGMAR1 3220/4885DPP8 3019/4885CYP2D6 3712/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | SIGMAR1 3220/4885DPP8 3019/4885CYP2D6 3712/4885 |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | SIGMAR1 3220/4885DPP8 3019/4885CYP2D6 3712/4885 |
| US-20230089255-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | DGKA, DGKG, DGKB | SIGMAR1 4695/4885DPP8 1111/4885CYP2D6 4386/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | SIGMAR1 3220/4885DPP8 3019/4885CYP2D6 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.